GMU Developing Proteomic Profile to Personalize Gleevec Treatment for CRC; Novartis Provides Funding

If the researchers are successful, GMU's Emanuel Petricoin believes it could lead to the development of the first ever protein activation companion assay.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.